The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 09, 2019
Filed:
Feb. 10, 2017
Applicant:
Biointeractions Ltd., Reading, GB;
Inventors:
Fanny Burrows, Reading, GB;
John E. Mckendrick, Reading, GB;
Alan Rhodes, Reading, GB;
Simon J. Onis, Reading, GB;
Shivpal S. Sandhu, Farnham Common, GB;
Assignee:
BioInteractions Ltd., Reading, GB;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C08F 18/22 (2006.01); A61L 33/00 (2006.01); C08F 222/02 (2006.01); A61L 27/34 (2006.01); A61L 31/10 (2006.01); C07F 9/10 (2006.01); C07F 9/6574 (2006.01); A61L 29/08 (2006.01); A61L 29/14 (2006.01); A61L 29/16 (2006.01); A61L 31/14 (2006.01); A61L 31/16 (2006.01); A61L 33/06 (2006.01); C08F 230/02 (2006.01); C07F 9/09 (2006.01); C08F 220/18 (2006.01); C08F 220/28 (2006.01); C09D 133/14 (2006.01); G02B 1/04 (2006.01); C07F 9/40 (2006.01); C07F 9/06 (2006.01); C07F 9/08 (2006.01); C07F 9/32 (2006.01); C07F 9/36 (2006.01); C08F 130/02 (2006.01); C08F 122/02 (2006.01); C08F 30/02 (2006.01); C08F 8/40 (2006.01); C08F 8/30 (2006.01); C08F 16/14 (2006.01); C08F 216/14 (2006.01); C08F 116/14 (2006.01);
U.S. Cl.
CPC ...
A61L 33/0023 (2013.01); A61L 27/34 (2013.01); A61L 29/085 (2013.01); A61L 29/14 (2013.01); A61L 29/16 (2013.01); A61L 31/10 (2013.01); A61L 31/14 (2013.01); A61L 31/16 (2013.01); A61L 33/064 (2013.01); C07F 9/091 (2013.01); C07F 9/106 (2013.01); C07F 9/65742 (2013.01); C08F 220/18 (2013.01); C08F 220/28 (2013.01); C08F 222/02 (2013.01); C08F 230/02 (2013.01); C09D 133/14 (2013.01); G02B 1/043 (2013.01); C07B 2200/11 (2013.01); C07F 9/062 (2013.01); C07F 9/08 (2013.01); C07F 9/32 (2013.01); C07F 9/3205 (2013.01); C07F 9/36 (2013.01); C07F 9/40 (2013.01); C07F 9/4078 (2013.01); C08F 8/30 (2013.01); C08F 8/40 (2013.01); C08F 16/14 (2013.01); C08F 18/22 (2013.01); C08F 30/02 (2013.01); C08F 116/14 (2013.01); C08F 122/02 (2013.01); C08F 130/02 (2013.01); C08F 216/14 (2013.01); C08F 2220/1825 (2013.01); C08F 2220/281 (2013.01); C08F 2220/285 (2013.01);
Abstract
New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibility, hydrophilicity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform.